Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-08-18

AUTHORS

Takeo Yasu, Takaaki Konuma, Seiko Kato, Yosuke Kurokawa, Satoshi Takahashi, Arinobu Tojo

ABSTRACT

Voriconazole (VRC) is widely used as prophylaxis and in the treatment of invasive fungal disease (IFD) after allogeneic hematopoietic cell transplantation (HCT). We retrospectively examined the results of VRC therapeutic drug monitoring (TDM) in allogeneic HCT recipients. A total of 474 samples were obtained from 59 adult patients who received VRC during the first 100 days following HCT between 2009 and 2014 in our institute. Seventeen patients received VRC for prophylaxis of IFD, and 42 received VRC for the empirical or preemptive therapy for IFD. A total of 299 samples (63 %) were obtained during the administration of the intravenous form of VRC. The median VRC daily dose based on the actual body weight was 6.68 mg/kg/day (range, 1.92–10.41 mg/kg/day). The median VRC trough level was 0.99 mg/l (range, <0.09–5.45 mg/l). The multivariate analysis using a logistic regression model demonstrated significantly higher VRC trough levels (≥1.0 mg/l) in males (P < 0.001), empirical or preemptive therapy (P = 0.002), VRC daily dose based on the actual body weight ≥7 mg/kg/day (P < 0.001), and concomitant use of lansoprazole as compared to rabeprazole (P < 0.001). The concomitant use of calcineurin inhibitors and corticosteroids had no effects on VRC trough levels in multivariate analysis. These data suggest that lansoprazole and rabeprazole have different effects on the plasma VRC trough levels in the allogeneic HCT recipients. More... »

PAGES

1845-1851

References to SciGraph publications

  • 2014-03-25. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2015-06-13. Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review in CLINICAL PHARMACOKINETICS
  • 2007-06-25. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole in BONE MARROW TRANSPLANTATION
  • 2012-12-03. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics in BONE MARROW TRANSPLANTATION
  • 2009-12-07. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring in BONE MARROW TRANSPLANTATION
  • 2006-07. Pharmacokinetic/Pharmacodynamic Profile of Voriconazole in CLINICAL PHARMACOKINETICS
  • 2013-02-26. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events in BMC INFECTIOUS DISEASES
  • 2006-09. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors in DRUG SAFETY
  • 2005-01-17. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients in BONE MARROW TRANSPLANTATION
  • 2015-02-20. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients—an evidence-based approach in ANNALS OF HEMATOLOGY
  • 2009-03-09. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients in BONE MARROW TRANSPLANTATION
  • 2014-02-19. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update in DRUG SAFETY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00277-016-2782-z

    DOI

    http://dx.doi.org/10.1007/s00277-016-2782-z

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1007715000

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/27535751


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Oral", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adolescent", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antifungal Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Body Weight", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bone Marrow Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cord Blood Stem Cell Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Interactions", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Monitoring", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hematologic Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Injections, Intravenous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lansoprazole", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mycoses", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Myelodysplastic Syndromes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Postoperative Complications", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rabeprazole", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transplantation Conditioning", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transplantation, Homologous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Voriconazole", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Young Adult", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.26999.3d", 
              "name": [
                "Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yasu", 
            "givenName": "Takeo", 
            "id": "sg:person.014370714515.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014370714515.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.26999.3d", 
              "name": [
                "Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Konuma", 
            "givenName": "Takaaki", 
            "id": "sg:person.01350075427.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350075427.97"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.26999.3d", 
              "name": [
                "Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kato", 
            "givenName": "Seiko", 
            "id": "sg:person.015266563712.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015266563712.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.26999.3d", 
              "name": [
                "Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kurokawa", 
            "givenName": "Yosuke", 
            "id": "sg:person.01160652043.78", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160652043.78"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.26999.3d", 
              "name": [
                "Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Takahashi", 
            "givenName": "Satoshi", 
            "id": "sg:person.0721047700.17", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721047700.17"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.26999.3d", 
              "name": [
                "Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tojo", 
            "givenName": "Arinobu", 
            "id": "sg:person.0703364434.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703364434.08"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00002018-200629090-00002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021468837", 
              "https://doi.org/10.2165/00002018-200629090-00002"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00277-015-2333-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002994605", 
              "https://doi.org/10.1007/s00277-015-2333-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2009.345", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051227168", 
              "https://doi.org/10.1038/bmt.2009.345"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12185-014-1529-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037640834", 
              "https://doi.org/10.1007/s12185-014-1529-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-200645070-00002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037510163", 
              "https://doi.org/10.2165/00003088-200645070-00002"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40264-014-0144-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037134279", 
              "https://doi.org/10.1007/s40264-014-0144-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2334-13-105", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023825382", 
              "https://doi.org/10.1186/1471-2334-13-105"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40262-015-0297-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028441768", 
              "https://doi.org/10.1007/s40262-015-0297-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1704828", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002160645", 
              "https://doi.org/10.1038/sj.bmt.1704828"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1705754", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051819372", 
              "https://doi.org/10.1038/sj.bmt.1705754"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2012.244", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028358194", 
              "https://doi.org/10.1038/bmt.2012.244"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2009.38", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024712217", 
              "https://doi.org/10.1038/bmt.2009.38"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2016-08-18", 
        "datePublishedReg": "2016-08-18", 
        "description": "Voriconazole (VRC) is widely used as prophylaxis and in the treatment of invasive fungal disease (IFD) after allogeneic hematopoietic cell transplantation (HCT). We retrospectively examined the results of VRC therapeutic drug monitoring (TDM) in allogeneic HCT recipients. A total of 474 samples were obtained from 59 adult patients who received VRC during the first 100\u00a0days following HCT between 2009 and 2014 in our institute. Seventeen patients received VRC for prophylaxis of IFD, and 42 received VRC for the empirical or preemptive therapy for IFD. A total of 299 samples (63\u00a0%) were obtained during the administration of the intravenous form of VRC. The median VRC daily dose based on the actual body weight was 6.68\u00a0mg/kg/day (range, 1.92\u201310.41\u00a0mg/kg/day). The median VRC trough level was 0.99\u00a0mg/l (range, <0.09\u20135.45\u00a0mg/l). The multivariate analysis using a logistic regression model demonstrated significantly higher VRC trough levels (\u22651.0\u00a0mg/l) in males (P\u2009<\u20090.001), empirical or preemptive therapy (P\u2009=\u20090.002), VRC daily dose based on the actual body weight \u22657\u00a0mg/kg/day (P\u2009<\u20090.001), and concomitant use of lansoprazole as compared to rabeprazole (P\u2009<\u20090.001). The concomitant use of calcineurin inhibitors and corticosteroids had no effects on VRC trough levels in multivariate analysis. These data suggest that lansoprazole and rabeprazole have different effects on the plasma VRC trough levels in the allogeneic HCT recipients.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00277-016-2782-z", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.5921568", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1358129", 
            "issn": [
              "0939-5555", 
              "1432-0584"
            ], 
            "name": "Annals of Hematology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "11", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "95"
          }
        ], 
        "keywords": [
          "invasive fungal disease", 
          "hematopoietic cell transplantation", 
          "allogeneic HCT recipients", 
          "trough levels", 
          "actual body weight", 
          "therapeutic drug monitoring", 
          "HCT recipients", 
          "preemptive therapy", 
          "concomitant use", 
          "body weight", 
          "prophylaxis of IFD", 
          "allogeneic hematopoietic cell transplant recipients", 
          "multivariate analysis", 
          "allogeneic hematopoietic cell transplantation", 
          "hematopoietic cell transplant recipients", 
          "cell transplant recipients", 
          "voriconazole trough levels", 
          "logistic regression models", 
          "transplant recipients", 
          "adult patients", 
          "intravenous form", 
          "daily dose", 
          "calcineurin inhibitors", 
          "cell transplantation", 
          "drug monitoring", 
          "voriconazole", 
          "lansoprazole", 
          "recipients", 
          "prophylaxis", 
          "patients", 
          "therapy", 
          "rabeprazole", 
          "dose", 
          "different effects", 
          "regression models", 
          "days", 
          "total", 
          "corticosteroids", 
          "transplantation", 
          "levels", 
          "fungal diseases", 
          "disease", 
          "administration", 
          "treatment", 
          "weight", 
          "inhibitors", 
          "males", 
          "effect", 
          "use", 
          "samples", 
          "Institute", 
          "analysis", 
          "monitoring", 
          "data", 
          "results", 
          "form", 
          "model"
        ], 
        "name": "Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients", 
        "pagination": "1845-1851", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1007715000"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00277-016-2782-z"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "27535751"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00277-016-2782-z", 
          "https://app.dimensions.ai/details/publication/pub.1007715000"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T17:03", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_696.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00277-016-2782-z"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2782-z'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2782-z'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2782-z'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-016-2782-z'


     

    This table displays all metadata directly associated to this object as RDF triples.

    309 TRIPLES      21 PREDICATES      120 URIs      100 LITERALS      33 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00277-016-2782-z schema:about N004406dfeb60401da72917f803dd9f4e
    2 N068ae4968bf74adfa0f5ea50c7e6c775
    3 N0cb5bb9f58904353b173c166b329b676
    4 N0f122307fa6f4d8dab71d0a8fb9858a4
    5 N16246040428e46fda82710b41f5c3cd3
    6 N177c6c68f3c2476bb54476b25aba9809
    7 N1a7fc29a3ced45609ae1e897d86bd263
    8 N25740c921bd94fc0b972e5271fa826fe
    9 N4033491df7594588a10578c3a27d92c8
    10 N45bc436e5cae4cbd89bb3fbd4e564e2a
    11 N50cd676ff6ab4c3eac503078577ecc9a
    12 N51703b8724e14041b0558bcf02e0177f
    13 N5db7f32309024fa58bb38056b81469a9
    14 N60b444acec424784b14d4871f2fa49bd
    15 N64fe98d21ef948cf860b6c8c572c17f8
    16 N6980795e6ab94edda39e2ef5bcdd61df
    17 N8438f55aa14a40dfad636b2587f9a4c0
    18 N8cc0c5c2403e4f3e805b8f829d37aad5
    19 Nb795ba62efd64154aeff4889c0a3eb9d
    20 Nbc9fe4ae32da4c7a9ce08ef6c2f774d0
    21 Nc66e70c5b0474f15836ec64ba6565065
    22 Nd337be2e38da450790f1245dfe1ec21c
    23 Nd3a05bad28ed43a3af3f62e59d634ec4
    24 Nde9e6e332b6c4eac8a79bc3494ad9ccd
    25 Ne5955e3d1a5d45ac8d548e03c06b5dd3
    26 Ne82c037cffaa4128916b35539ecd9c3b
    27 anzsrc-for:11
    28 anzsrc-for:1103
    29 schema:author Nc474bc8ec9bc47f29cd8c412cefec222
    30 schema:citation sg:pub.10.1007/s00277-015-2333-z
    31 sg:pub.10.1007/s12185-014-1529-7
    32 sg:pub.10.1007/s40262-015-0297-8
    33 sg:pub.10.1007/s40264-014-0144-0
    34 sg:pub.10.1038/bmt.2009.345
    35 sg:pub.10.1038/bmt.2009.38
    36 sg:pub.10.1038/bmt.2012.244
    37 sg:pub.10.1038/sj.bmt.1704828
    38 sg:pub.10.1038/sj.bmt.1705754
    39 sg:pub.10.1186/1471-2334-13-105
    40 sg:pub.10.2165/00002018-200629090-00002
    41 sg:pub.10.2165/00003088-200645070-00002
    42 schema:datePublished 2016-08-18
    43 schema:datePublishedReg 2016-08-18
    44 schema:description Voriconazole (VRC) is widely used as prophylaxis and in the treatment of invasive fungal disease (IFD) after allogeneic hematopoietic cell transplantation (HCT). We retrospectively examined the results of VRC therapeutic drug monitoring (TDM) in allogeneic HCT recipients. A total of 474 samples were obtained from 59 adult patients who received VRC during the first 100 days following HCT between 2009 and 2014 in our institute. Seventeen patients received VRC for prophylaxis of IFD, and 42 received VRC for the empirical or preemptive therapy for IFD. A total of 299 samples (63 %) were obtained during the administration of the intravenous form of VRC. The median VRC daily dose based on the actual body weight was 6.68 mg/kg/day (range, 1.92–10.41 mg/kg/day). The median VRC trough level was 0.99 mg/l (range, <0.09–5.45 mg/l). The multivariate analysis using a logistic regression model demonstrated significantly higher VRC trough levels (≥1.0 mg/l) in males (P < 0.001), empirical or preemptive therapy (P = 0.002), VRC daily dose based on the actual body weight ≥7 mg/kg/day (P < 0.001), and concomitant use of lansoprazole as compared to rabeprazole (P < 0.001). The concomitant use of calcineurin inhibitors and corticosteroids had no effects on VRC trough levels in multivariate analysis. These data suggest that lansoprazole and rabeprazole have different effects on the plasma VRC trough levels in the allogeneic HCT recipients.
    45 schema:genre article
    46 schema:isAccessibleForFree false
    47 schema:isPartOf N4660f007ddf04123954bc4b156e344c4
    48 N8d5225bae33c406e8b730909e175f27f
    49 sg:journal.1358129
    50 schema:keywords HCT recipients
    51 Institute
    52 actual body weight
    53 administration
    54 adult patients
    55 allogeneic HCT recipients
    56 allogeneic hematopoietic cell transplant recipients
    57 allogeneic hematopoietic cell transplantation
    58 analysis
    59 body weight
    60 calcineurin inhibitors
    61 cell transplant recipients
    62 cell transplantation
    63 concomitant use
    64 corticosteroids
    65 daily dose
    66 data
    67 days
    68 different effects
    69 disease
    70 dose
    71 drug monitoring
    72 effect
    73 form
    74 fungal diseases
    75 hematopoietic cell transplant recipients
    76 hematopoietic cell transplantation
    77 inhibitors
    78 intravenous form
    79 invasive fungal disease
    80 lansoprazole
    81 levels
    82 logistic regression models
    83 males
    84 model
    85 monitoring
    86 multivariate analysis
    87 patients
    88 preemptive therapy
    89 prophylaxis
    90 prophylaxis of IFD
    91 rabeprazole
    92 recipients
    93 regression models
    94 results
    95 samples
    96 therapeutic drug monitoring
    97 therapy
    98 total
    99 transplant recipients
    100 transplantation
    101 treatment
    102 trough levels
    103 use
    104 voriconazole
    105 voriconazole trough levels
    106 weight
    107 schema:name Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients
    108 schema:pagination 1845-1851
    109 schema:productId N51b757d04be74da69beab0ad64701712
    110 Ncb828f759e464de4a06871d48922d881
    111 Nf4f66514f8d14d2f892f808832668928
    112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007715000
    113 https://doi.org/10.1007/s00277-016-2782-z
    114 schema:sdDatePublished 2022-08-04T17:03
    115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    116 schema:sdPublisher N23e8326232534fc3b98743648e6fe2f1
    117 schema:url https://doi.org/10.1007/s00277-016-2782-z
    118 sgo:license sg:explorer/license/
    119 sgo:sdDataset articles
    120 rdf:type schema:ScholarlyArticle
    121 N004406dfeb60401da72917f803dd9f4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Drug Interactions
    123 rdf:type schema:DefinedTerm
    124 N068ae4968bf74adfa0f5ea50c7e6c775 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Myelodysplastic Syndromes
    126 rdf:type schema:DefinedTerm
    127 N0cb5bb9f58904353b173c166b329b676 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Injections, Intravenous
    129 rdf:type schema:DefinedTerm
    130 N0f122307fa6f4d8dab71d0a8fb9858a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Young Adult
    132 rdf:type schema:DefinedTerm
    133 N16246040428e46fda82710b41f5c3cd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Transplantation Conditioning
    135 rdf:type schema:DefinedTerm
    136 N177c6c68f3c2476bb54476b25aba9809 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Middle Aged
    138 rdf:type schema:DefinedTerm
    139 N1a7fc29a3ced45609ae1e897d86bd263 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Mycoses
    141 rdf:type schema:DefinedTerm
    142 N23e8326232534fc3b98743648e6fe2f1 schema:name Springer Nature - SN SciGraph project
    143 rdf:type schema:Organization
    144 N25740c921bd94fc0b972e5271fa826fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Adult
    146 rdf:type schema:DefinedTerm
    147 N4033491df7594588a10578c3a27d92c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Bone Marrow Transplantation
    149 rdf:type schema:DefinedTerm
    150 N45bc436e5cae4cbd89bb3fbd4e564e2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Aged
    152 rdf:type schema:DefinedTerm
    153 N4660f007ddf04123954bc4b156e344c4 schema:issueNumber 11
    154 rdf:type schema:PublicationIssue
    155 N50cd676ff6ab4c3eac503078577ecc9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Retrospective Studies
    157 rdf:type schema:DefinedTerm
    158 N51703b8724e14041b0558bcf02e0177f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Administration, Oral
    160 rdf:type schema:DefinedTerm
    161 N51b757d04be74da69beab0ad64701712 schema:name pubmed_id
    162 schema:value 27535751
    163 rdf:type schema:PropertyValue
    164 N5db7f32309024fa58bb38056b81469a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Voriconazole
    166 rdf:type schema:DefinedTerm
    167 N60b444acec424784b14d4871f2fa49bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Male
    169 rdf:type schema:DefinedTerm
    170 N64fe98d21ef948cf860b6c8c572c17f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Transplantation, Homologous
    172 rdf:type schema:DefinedTerm
    173 N6548b3094a4c4b478900c5d235257f56 rdf:first sg:person.0703364434.08
    174 rdf:rest rdf:nil
    175 N6980795e6ab94edda39e2ef5bcdd61df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Drug Monitoring
    177 rdf:type schema:DefinedTerm
    178 N70bfa560a6d14cfa958a99f90f2fa978 rdf:first sg:person.0721047700.17
    179 rdf:rest N6548b3094a4c4b478900c5d235257f56
    180 N8438f55aa14a40dfad636b2587f9a4c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Lansoprazole
    182 rdf:type schema:DefinedTerm
    183 N8cc0c5c2403e4f3e805b8f829d37aad5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Cord Blood Stem Cell Transplantation
    185 rdf:type schema:DefinedTerm
    186 N8d5225bae33c406e8b730909e175f27f schema:volumeNumber 95
    187 rdf:type schema:PublicationVolume
    188 Nb795ba62efd64154aeff4889c0a3eb9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Rabeprazole
    190 rdf:type schema:DefinedTerm
    191 Nbc9fe4ae32da4c7a9ce08ef6c2f774d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Body Weight
    193 rdf:type schema:DefinedTerm
    194 Nc474bc8ec9bc47f29cd8c412cefec222 rdf:first sg:person.014370714515.23
    195 rdf:rest Ne659fd51f1174495bccd2e0bf5d6325f
    196 Nc63c9e96d50c4240a49e861f0d9033dd rdf:first sg:person.01160652043.78
    197 rdf:rest N70bfa560a6d14cfa958a99f90f2fa978
    198 Nc66e70c5b0474f15836ec64ba6565065 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Hematologic Neoplasms
    200 rdf:type schema:DefinedTerm
    201 Ncb828f759e464de4a06871d48922d881 schema:name doi
    202 schema:value 10.1007/s00277-016-2782-z
    203 rdf:type schema:PropertyValue
    204 Nd337be2e38da450790f1245dfe1ec21c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    205 schema:name Humans
    206 rdf:type schema:DefinedTerm
    207 Nd3a05bad28ed43a3af3f62e59d634ec4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    208 schema:name Postoperative Complications
    209 rdf:type schema:DefinedTerm
    210 Ndbcd77e3ccc64191ae5ec94848b75451 rdf:first sg:person.015266563712.53
    211 rdf:rest Nc63c9e96d50c4240a49e861f0d9033dd
    212 Nde9e6e332b6c4eac8a79bc3494ad9ccd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    213 schema:name Antifungal Agents
    214 rdf:type schema:DefinedTerm
    215 Ne5955e3d1a5d45ac8d548e03c06b5dd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    216 schema:name Adolescent
    217 rdf:type schema:DefinedTerm
    218 Ne659fd51f1174495bccd2e0bf5d6325f rdf:first sg:person.01350075427.97
    219 rdf:rest Ndbcd77e3ccc64191ae5ec94848b75451
    220 Ne82c037cffaa4128916b35539ecd9c3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    221 schema:name Female
    222 rdf:type schema:DefinedTerm
    223 Nf4f66514f8d14d2f892f808832668928 schema:name dimensions_id
    224 schema:value pub.1007715000
    225 rdf:type schema:PropertyValue
    226 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    227 schema:name Medical and Health Sciences
    228 rdf:type schema:DefinedTerm
    229 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    230 schema:name Clinical Sciences
    231 rdf:type schema:DefinedTerm
    232 sg:grant.5921568 http://pending.schema.org/fundedItem sg:pub.10.1007/s00277-016-2782-z
    233 rdf:type schema:MonetaryGrant
    234 sg:journal.1358129 schema:issn 0939-5555
    235 1432-0584
    236 schema:name Annals of Hematology
    237 schema:publisher Springer Nature
    238 rdf:type schema:Periodical
    239 sg:person.01160652043.78 schema:affiliation grid-institutes:grid.26999.3d
    240 schema:familyName Kurokawa
    241 schema:givenName Yosuke
    242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160652043.78
    243 rdf:type schema:Person
    244 sg:person.01350075427.97 schema:affiliation grid-institutes:grid.26999.3d
    245 schema:familyName Konuma
    246 schema:givenName Takaaki
    247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350075427.97
    248 rdf:type schema:Person
    249 sg:person.014370714515.23 schema:affiliation grid-institutes:grid.26999.3d
    250 schema:familyName Yasu
    251 schema:givenName Takeo
    252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014370714515.23
    253 rdf:type schema:Person
    254 sg:person.015266563712.53 schema:affiliation grid-institutes:grid.26999.3d
    255 schema:familyName Kato
    256 schema:givenName Seiko
    257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015266563712.53
    258 rdf:type schema:Person
    259 sg:person.0703364434.08 schema:affiliation grid-institutes:grid.26999.3d
    260 schema:familyName Tojo
    261 schema:givenName Arinobu
    262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703364434.08
    263 rdf:type schema:Person
    264 sg:person.0721047700.17 schema:affiliation grid-institutes:grid.26999.3d
    265 schema:familyName Takahashi
    266 schema:givenName Satoshi
    267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721047700.17
    268 rdf:type schema:Person
    269 sg:pub.10.1007/s00277-015-2333-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1002994605
    270 https://doi.org/10.1007/s00277-015-2333-z
    271 rdf:type schema:CreativeWork
    272 sg:pub.10.1007/s12185-014-1529-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037640834
    273 https://doi.org/10.1007/s12185-014-1529-7
    274 rdf:type schema:CreativeWork
    275 sg:pub.10.1007/s40262-015-0297-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028441768
    276 https://doi.org/10.1007/s40262-015-0297-8
    277 rdf:type schema:CreativeWork
    278 sg:pub.10.1007/s40264-014-0144-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037134279
    279 https://doi.org/10.1007/s40264-014-0144-0
    280 rdf:type schema:CreativeWork
    281 sg:pub.10.1038/bmt.2009.345 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051227168
    282 https://doi.org/10.1038/bmt.2009.345
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.1038/bmt.2009.38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024712217
    285 https://doi.org/10.1038/bmt.2009.38
    286 rdf:type schema:CreativeWork
    287 sg:pub.10.1038/bmt.2012.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028358194
    288 https://doi.org/10.1038/bmt.2012.244
    289 rdf:type schema:CreativeWork
    290 sg:pub.10.1038/sj.bmt.1704828 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002160645
    291 https://doi.org/10.1038/sj.bmt.1704828
    292 rdf:type schema:CreativeWork
    293 sg:pub.10.1038/sj.bmt.1705754 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051819372
    294 https://doi.org/10.1038/sj.bmt.1705754
    295 rdf:type schema:CreativeWork
    296 sg:pub.10.1186/1471-2334-13-105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023825382
    297 https://doi.org/10.1186/1471-2334-13-105
    298 rdf:type schema:CreativeWork
    299 sg:pub.10.2165/00002018-200629090-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021468837
    300 https://doi.org/10.2165/00002018-200629090-00002
    301 rdf:type schema:CreativeWork
    302 sg:pub.10.2165/00003088-200645070-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037510163
    303 https://doi.org/10.2165/00003088-200645070-00002
    304 rdf:type schema:CreativeWork
    305 grid-institutes:grid.26999.3d schema:alternateName Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan
    306 Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    307 schema:name Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan
    308 Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    309 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...